Related Experiment Video

Updated: May 19, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Rosuvastatin-induced high-density lipoprotein changes in patients who underwent percutaneous coronary intervention

Kyeong Ho Yun1, Seoung-Nam Shin, Jum Suk Ko

  • 1Department of Cardiovascular Medicine, Regional Cardiocerebrovascular Center, Wonkwang University Hospital, Iksan, Republic of Korea. ards7210@yahoo.co.kr

Journal of Cardiology
|August 14, 2012
PubMed

Insights

Baseline high-density lipoprotein cholesterol (HDL-C) levels predict rosuvastatin-induced HDL-C changes in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS). However, these HDL-C changes do not predict major adverse cardiovascular events (MACE).

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Lipidology

Background:

  • The clinical significance of statin-induced changes in high-density lipoprotein cholesterol (HDL-C) remains unclear.
  • Investigating factors influencing rosuvastatin-induced HDL-C modifications and their association with cardiovascular events is crucial.

Purpose of the Study:

  • To determine factors affecting rosuvastatin-induced HDL-C changes in patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) undergoing percutaneous coronary intervention (PCI).
  • To assess the correlation between these HDL-C changes and 12-month major adverse cardiovascular events (MACE).

Main Methods:

  • Analysis of 556 NSTE-ACS patients treated with rosuvastatin post-PCI.
  • Measurement of serum lipids (including HDL-C and triglycerides) at baseline and 4 weeks.
  • Assessment of the relationship between on-treatment lipid levels, baseline lipids, and 12-month MACE.

Main Results:

  • Rosuvastatin increased mean HDL-C by 4.3% (1.1 mg/dl), with increases observed in 56.1% and decreases in 43.9% of patients.
  • Changes in HDL-C were inversely correlated with baseline HDL-C levels (r=-0.379, p<0.001) and positively correlated with triglyceride changes (r=-0.212, p<0.001).
  • Baseline HDL-C was the sole significant predictor of rosuvastatin-induced HDL-C changes; 12-month MACE incidence was similar regardless of HDL-C change direction (11.9% vs. 12.3%, p=0.875).

Conclusions:

  • Baseline HDL-C concentration independently predicts rosuvastatin-induced HDL-C alterations.
  • Statin-associated HDL-C changes do not appear to be a predictor of 12-month MACE in NSTE-ACS patients post-PCI.
Abstract

More Related Videos

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein07:29

Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein

Published on: October 12, 2017

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...